Literature DB >> 26867783

Plasma cells in primary melanoma. Prognostic significance and possible role of IgA.

Francesca M Bosisio1,2, James S Wilmott3, Nathalie Volders1, Marjorie Mercier4, Jasper Wouters1, Marguerite Stas5, Willeke Am Blokx6, Daniela Massi7, John F Thompson3, Richard A Scolyer3,8, Nicolas van Baren4, Joost J van den Oord1.   

Abstract

Melanoma is not only one of the most immunogenic cancers but also one of the most effective cancers at subverting host immunity. The role of T lymphocytes in tumor immunity has been extensively studied in melanoma, whereas less is known about the importance of B lymphocytes. The effects of plasma cells (PCs), in particular, are still obscure. The aim of this study was to characterize pathological features and clinical outcome of primary cutaneous melanomas associated with PCs. Moreover, we investigated the origins of the melanoma-associated PCs. Finally, we studied the outcome of patients with primary melanomas with PCs. We reviewed 710 melanomas to correlate the presence of PCs with histological prognostic markers. Immunohistochemistry for CD138 and heavy and light chains was performed in primary melanomas (PM) and in loco-regional lymph nodes (LN), both metastatic and not metastatic. In three PM and nine LN with frozen material, VDJ-rearrangement was analyzed by Gene Scan Analysis. Survival analysis was performed on a group of 85 primary melanomas >2 mm in thickness. Forty-one cases (3.7%) showed clusters/sheets of PCs. PC-rich melanomas occurred at an older age and were thicker, more often ulcerated and more mitotically active (P<0.05). PCs were polyclonal and often expressed IgA in addition to IgG. In LN, clusters/sheets of IgA+ PCs were found both in the sinuses and subcapsular areas. Analysis of VDJ-rearrangements showed the IgA to be oligoclonal. Melanomas with clusters/sheets of PCs had a significantly worse survival compared with melanomas without PCs while, interestingly, melanomas with sparse PCs were associated with a better clinical outcome (P=0.002). In conclusion, melanomas with sheets/clusters of PCs are associated with worse prognosis. IgG and IgA are the isotypes predominantly produced by these PCs. IgA oligoclonality suggests an antigen-driven response that facilitates melanoma progression by a hitherto unknown mechanism.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26867783     DOI: 10.1038/modpathol.2016.28

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  43 in total

Review 1.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm.

Authors:  Subhra K Biswas; Alberto Mantovani
Journal:  Nat Immunol       Date:  2010-09-20       Impact factor: 25.606

Review 2.  The immune microenvironment: a major player in human cancers.

Authors:  W H Fridman; R Remark; J Goc; N A Giraldo; E Becht; Scott A Hammond; D Damotte; M-C Dieu-Nosjean; Catherine Sautès-Fridman
Journal:  Int Arch Allergy Immunol       Date:  2014-05-13       Impact factor: 2.749

3.  Mesenteric lymph nodes are not required for an intestinal immunoglobulin A response to oral cholera toxin.

Authors:  Anika Hahn; Nadja Thiessen; Reinhard Pabst; Manuela Buettner; Ulrike Bode
Journal:  Immunology       Date:  2009-11-16       Impact factor: 7.397

Review 4.  Revisiting the role of B cells in skin immune surveillance.

Authors:  Isioma U Egbuniwe; Sophia N Karagiannis; Frank O Nestle; Katie E Lacy
Journal:  Trends Immunol       Date:  2015-01-21       Impact factor: 16.687

Review 5.  Prognostic and predictive significance of immune cells infiltrating cutaneous melanoma.

Authors:  Andrea Ladányi
Journal:  Pigment Cell Melanoma Res       Date:  2015-04-20       Impact factor: 4.693

6.  The tumor microenvironment at a glance.

Authors:  Frances R Balkwill; Melania Capasso; Thorsten Hagemann
Journal:  J Cell Sci       Date:  2012-12-01       Impact factor: 5.285

Review 7.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

8.  Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients.

Authors:  Roy S Herbst; Jean-Charles Soria; Marcin Kowanetz; Gregg D Fine; Omid Hamid; Michael S Gordon; Jeffery A Sosman; David F McDermott; John D Powderly; Scott N Gettinger; Holbrook E K Kohrt; Leora Horn; Donald P Lawrence; Sandra Rost; Maya Leabman; Yuanyuan Xiao; Ahmad Mokatrin; Hartmut Koeppen; Priti S Hegde; Ira Mellman; Daniel S Chen; F Stephen Hodi
Journal:  Nature       Date:  2014-11-27       Impact factor: 49.962

9.  Model predicting survival in stage I melanoma based on tumor progression.

Authors:  W H Clark; D E Elder; D Guerry; L E Braitman; B J Trock; D Schultz; M Synnestvedt; A C Halpern
Journal:  J Natl Cancer Inst       Date:  1989-12-20       Impact factor: 13.506

10.  Immunomics in Skin Cancer - Improvement in Diagnosis, Prognosis and Therapy Monitoring.

Authors:  Amanda Bulman; Monica Neagu; Carolina Constantin
Journal:  Curr Proteomics       Date:  2013-09       Impact factor: 0.837

View more
  24 in total

1.  Tumor infiltrating B-cells signal functional humoral immune responses in breast cancer.

Authors:  Soizic Garaud; Laurence Buisseret; Cinzia Solinas; Chunyan Gu-Trantien; Alexandre de Wind; Gert Van den Eynden; Celine Naveaux; Jean-Nicolas Lodewyckx; Anaïs Boisson; Hughes Duvillier; Ligia Craciun; Lieveke Ameye; Isabelle Veys; Marianne Paesmans; Denis Larsimont; Martine Piccart-Gebhart; Karen Willard-Gallo
Journal:  JCI Insight       Date:  2019-08-13

Review 2.  Immunoplasticity in cutaneous melanoma: beyond pure morphology.

Authors:  Francesca Maria Bosisio; Joost J van den Oord
Journal:  Virchows Arch       Date:  2017-01-05       Impact factor: 4.064

Review 3.  Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma.

Authors:  Nicolas Jacquelot; Jonathan M Pitt; David P Enot; Maria Paula Roberti; Connie P M Duong; Sylvie Rusakiewicz; Alexander M Eggermont; Laurence Zitvogel
Journal:  Oncoimmunology       Date:  2017-03-07       Impact factor: 8.110

Review 4.  B cells and antibody production in melanoma.

Authors:  Jessica Da Gama Duarte; Janique M Peyper; Jonathan M Blackburn
Journal:  Mamm Genome       Date:  2018-09-03       Impact factor: 2.957

Review 5.  HYPE or HOPE: the prognostic value of infiltrating immune cells in cancer.

Authors:  Tristan A Barnes; Eitan Amir
Journal:  Br J Cancer       Date:  2017-07-13       Impact factor: 7.640

6.  Spatiotemporal Analysis of B Cell- and Antibody Secreting Cell-Subsets in Human Melanoma Reveals Metastasis-, Tumor Stage-, and Age-Associated Dynamics.

Authors:  Minyi Chen; Franziska Werner; Christine Wagner; Martin Simon; Erika Richtig; Kirsten D Mertz; Johannes Griss; Stephan N Wagner
Journal:  Front Cell Dev Biol       Date:  2021-05-21

7.  Prognostic value of tumor-infiltrating B lymphocytes and plasma cells in triple-negative breast cancer.

Authors:  Hajime Kuroda; Tsengelmaa Jamiyan; Rin Yamaguchi; Akinari Kakumoto; Akihito Abe; Oi Harada; Bayarmaa Enkhbat; Atsuko Masunaga
Journal:  Breast Cancer       Date:  2021-02-25       Impact factor: 4.239

Review 8.  The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities.

Authors:  Nicole J Flynn; Rajasekharan Somasundaram; Kimberly M Arnold; Jennifer Sims-Mourtada
Journal:  Target Oncol       Date:  2017-04       Impact factor: 4.864

9.  Conventional Versus Giant Basal Cell Carcinoma, a Review of 57 Cases: Histologic Differences Contributing to Excessive Growth.

Authors:  J Chase Purnell; Jerad M Gardner; J Ahmad Brown; Sara C Shalin
Journal:  Indian J Dermatol       Date:  2018 Mar-Apr       Impact factor: 1.494

10.  The Role of Tumor-Infiltrating B Cells in Tumor Immunity.

Authors:  Fei Fei Guo; Jiu Wei Cui
Journal:  J Oncol       Date:  2019-09-24       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.